Skip to main content

Day: August 9, 2024

TMTG Reports Second Quarter 2024 Results, Closes TV Streaming Deal

~ Ends Second Quarter with $344 Million Cash on Balance Sheet and No Debt ~ ~ Opens First Data Center to Power Custom-Built Content Delivery Network ~ ~ Adds TV Streaming Platform to Truth Social on iOS, Android, and Web ~ SARASOTA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, is announcing financial results for the fiscal quarter ending on June 30, 2024, and that it has filed its 10-Q with the Securities and Exchange Commission (the “SEC”) today. TMTG’s quarterly report and financials were reviewed by its independent registered public accounting firm Semple, Marchal & Cooper, LLP. In the second quarter, TMTG continued to strengthen its balance sheet. As of June 30, 2024, TMTG’s balance of cash and...

Continue reading

Doman Building Materials Group Ltd. Announces Second Quarter 2024 Financial Results

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Q2 2024 Financial Highlights(1):Revenues of $689.8 million Gross Margin at 15.7% Adjusted EBITDA(3) amounted to $50.6 million Net Earnings amounted to $17.0 million Quarterly dividend of $0.14 per share declared(4)VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) — Doman Building Materials Group Ltd. (“Doman” or “the Company”) (TSX:DBM) announced today its second quarter 2024 financial results(1) for the period ended June 30, 2024. For the three-month period ended June 30, 2024(1), consolidated revenues decreased 2.9% to $689.8 million, compared to $710.7 million in 2023. The decrease was largely due to the impact of a slowing in the construction...

Continue reading

BRT Apartments Corp. Files Second Quarter 2024 Financial Statements

GREAT NECK, N.Y., Aug. 09, 2024 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, announced that it has filed its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the Securities and Exchange Commission. The financial statements and supplemental financial information can be accessed on the Company’s investor relations website under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that own multi-family properties. As of June 30, 2024, BRT owns or has interests in 29 multi-family properties with 7,947 units in 11 states. For additional information on BRT’s...

Continue reading

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business. During the quarter, the company’s anti-TLR4 drug candidate, EB05 (paridiprubart), was selected by the U.S. Department of Health and Human Services for use in a U.S. government-funded platform study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Edesa is providing drug product for the trial as well as technical support at its own expense. In addition, the company reported today that it plans to continue utilizing its internal resources...

Continue reading

Motorsport Games Reports Second Quarter 2024 Financial Results 

Motorsport Games Reports Second Quarter 2024 Financial ResultsMotorsport Games Reports Second Quarter 2024 Financial ResultsMIAMI, Aug. 09, 2024 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) today reported financial results for its second quarter ended June 30, 2024. The Company has also posted the second quarter 2024 earnings slides highlighting key milestones that occurred during and subsequent to the period, which are accessible on the Company’s investor relations website. “We are pleased to have built upon the foundation that our successful launch of Le Mans Ultimate achieved in February 2024 in this quarter,” stated Stephen Hood, President and Chief Executive Officer of Motorsport Games. “For players, we’ve made significant improvements to the game through multiple...

Continue reading

FutureFuel Releases Second Quarter 2024 Results

Reports Net Income of $9.6 Million or $0.22 per Diluted Share, and Adjusted EBITDA of $6.9 Million CLAYTON, Mo., Aug. 09, 2024 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the second quarter ended June 30, 2024. Second quarter 2024 Financial Highlights (all comparisons are with the second quarter of 2023)Revenues were $72.4 million, a decrease of 15% or $12.9 million compared to $85.3 million. Net income was $9.6 million, or $0.22 per diluted share, up from a net loss of $9.9 million, or $0.23 per diluted share. Adjusted EBITDA(1) was $6.9 million, up from ($7.3) million.Six months 2024 Financial Highlights (all comparisons are with the first six months of 2023)Revenues were $130.7 million, a decrease of...

Continue reading

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

– Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – – Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction – MIAMI, Aug. 09, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2024. “We continue to make meaningful progress advancing our pipeline of innovative treatments for neurologic diseases,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. “In the second quarter, we completed...

Continue reading

Gencor Releases Third Quarter Fiscal 2024 Results

ORLANDO, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenues for the quarter ended June 30, 2024 decreased $2,326,000 to $25,551,000, from $27,877,000 for the quarter ended June 30, 2023. The decrease in revenues was in equipment sales recognized at a point in time and reduced parts sales. The lower revenues reflect the delayed timing of the shipment of orders. As a percent of sales, gross profit margins decreased to 23.9% in the quarter ended June 30, 2024, compared to 26.9% in the quarter ended June 30, 2023, on lower absorption from reduced production and lower parts sales. Product engineering and development expenses decreased by $21,000 to $824,000 for the quarter ended June 30, 2024, as compared to $845,000 for the quarter ended June...

Continue reading

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. “We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N-Tab™ oral peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic diseases,” said Miranda Toledano, Entera’s CEO. “Importantly, we are now just five months away from FDA’s potential landmark ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs, which we view as a major catalyst for EB613. We are especially keen to start our pivotal study of EB613 in a much wider population...

Continue reading

Symbotic Acquires Veo Robotics to Enhance Efficiency and Safety Innovation

Symbotic to integrate Veo Robotics’ patented FreeMove® intelligent 3D vision system to increase efficiency and safety innovation of collaborative industrial robot workcells WILMINGTON, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, announced it has acquired substantially all of the assets of Veo Robotics, an innovator in intelligent safeguarding for industrial robots. Assets purchased under this agreement include the FreeMove® 3D depth-sensing computer vision system for industrial workcells and all related intellectual property. By integrating FreeMove into its robotic warehouse automation system, Symbotic expects to increase productivity with more dynamic, flexible human-machine collaboration. “The innovative FreeMove vision system allows...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.